1983 Volume 14 Issue 2 Pages 216-218
Antithromobotic therapy is necessary and important to maintain the effective blood circulation in vascular surgery. In this report, MD-805, a new synthetic thrombin inhibitor, was evaluated as an anticoagulant agent for vascular surgery.
Fifteen patients with peripheral arterial occlusive disease underwent MD-805, therapy on the schedule described in method after vascular reconstruction The prognosis was resulted in 11 patients with patency and in 4 occlusion, as shown in Table 1. The blood examinations were as follows:
1. In the intravenous administration of 10-20mg/day, partial thromboplastin time (PTT), prothrombin time (PT) and thrombin time significantly prolonged and platelet aggregability due to ADP and collagen were depressed. Fibrinogen remarkably increased. The fibrinolytic system was almost unaffected.
2. In the oral administration of 300mg/day, coagulative and fibrinolytic systems did not manifest any change.
These results were detailed in Table 2.
Intravenous administration of 20mg/day of MD-805 seems to be enough to prevent thrombus formation. MD-805 therapy is considered to be a useful anticoagulant agent for vascular surgery.
